Pfizer (PFE), BioNTech SE (BNTX) Report Agreement with the U.K. for 30M Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Pfizer (PFE), BioNTech SE (BNTX) Report Agreement with the U.K. for 30M Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
July 21, 2020 8:42 AM EDT
Morgan Stanley analyst David Risinger reiterated an Equalweight rating and $36.00 price target on Pfizer (NYSE: PFE) following the company's COVID vaccine update. Results appear encouraging vs. MRNA and AZN, but x-trial comps are confounded.
Risinger await results from BNT162b2(full spike)... More
July 20, 2020 10:57 AM EDT
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $38.00 price target on Pfizer (NYSE: PFE), citing continued positive progress on its COVID vaccine.
The analyst commented, "We are encouraged by new data from Pfizer and partner BioNTech on the progress they are... More
July 17, 2020 7:29 AM EDT
By Francesco Guarascio
BRUSSELS (Reuters) - The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna (NASDAQ: MRNA), Sanofi and Johnson & Johnson (NYSE: JNJ) as well as biotech firms BioNtech (NASDAQ: BNTX) and CureVac, two EU sources told Reuters.
The talks follow a deal reached in June by four EU member states with AstraZeneca (NYSE: AZN) for the upfront purchase of 400 million doses of its potential COVID-19 vaccine, in... More
